Jamie E. Chaft on Muck Rack

Jamie E. Chaft

United States
As seen in: Nature, JAMA: Journal of the American Medical Association, Medscape, The New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, HMP Global Learning Network, Oncology Learning Network, Texas Medical Center, ONCOLOGY journal and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jamie E.

Contact Jamie E., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Adjuvant Nivolumab Fails to Improve DFS Regardless of PD-L1 Status in Non-Small Cell Lung Cancer

|
By Jamie E. Chaft
| Oncology Learning Network Verified
Clinical Summary: Design/Population: The phase 3 EA5142 (ALCHEMIST) trial randomized 935 patients with resected stage IB-IIIA EGFR/ALK-negative non-small cell lung cancer to receive eihter adjuvant nivolumab for up to 1 year or observation following standard adjuvant therapy. Key Outcomes: Adjuvant nivolumab did not improve disease-free survival in the overall population or in patients with PD-L1 expression ≥50%.
Open in Who Shared Issue with article?

Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer : A Randomized Clinical Trial

|
By Jamie E. Chaft, Zhuoxin Sun, Charles M. Rudin, Charles Simone, Kurt R. Oettel, David Kozono, Rajitha Sunkara, Bryan Faller, James M. Isbell, Vladimir Hugec, Jeffrey M. Clarke, Ramaswamy Govindan, Jacob Sands, John Heymach, Luis E Raez, Shakun Malik, Thomas E. Stinchcombe, Sumithra J. Mandrekar, Jeffrey Bradley, David E. Gerber, Everett E Vokes, David Gandara, Charles Staley, Suresh S. Ramalingam, Onkar V. Khullar, Asheesh Shipstone, Eric C. McGary, Ashita Talsania
| JAMA: Journal of the American Medical Association Verified
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer: A Randomized Clinical Trial Supplement 1. Supplement 2. eFigure 1. Disease-free survival sensitivity analysis excluding new primary lung cancers eFigure 2. Disease-free survival in patients with negative and low tumoral PD-L1 eTable 1. Grade 3-5 Treatment-related Toxicities per CTCAE v4.0 eTable 2. Treatment-related Grade 3-5 Events Occurring in ≥ 1% of patients (n,%) Supplement 3.
Open in Who Shared Issue with article?

Reply to “NeoADAURA: Can We Afford to Overlook Objective Response Rates?” and “Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?”

|
By Jamie E. Chaft, Walter Weder
| brnw.ch
We thank Fan et al1 and Woodard and Stiles2 for their comments on our article reporting the primary findings from the NeoADAURA study.3 Fan et al1 and Woodard and Stiles2 queried the use of major pathologic response (MPR) as a primary end point, with Fan et al1 proposing objective response rate (ORR) as an alternative.
Open in Who Shared Issue with article?
See all 34 licensed articles (61 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified